NCT07049575

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 12 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	Ruxolitinib Cream	Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Timeline

• Start date: 2025-11-03
• Primary completion: 2026-12-09
• Completion: 2026-12-09
• First posted: 2025-07-03
• Last updated: 2026-04-06

Locations

24 sites across 1 country: United States

Regulatory

• FDA-regulated drug study